Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice

Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation's largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization, today announced that Gilead will provide a $3.2 million grant over two years to support communities disproportionately impacted by the HIV epidemic in the United States, particularly communities of color. Gilead will directly fund the efforts of the HRC Foundation HRC's educational arm aimed at ending the HIV epidemic, as well as fund the organization's Transgender Justice Initiative.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005393/en/

This innovative initiative builds on core strengths of each organization, including Gilead's long-standing efforts to address healthcare disparities and HRC's leadership in advancing justice for LGBTQ+ communities for more than 40 years. It also builds on HRC's commitment to programmatic work that actively challenges systems, laws and policies that disproportionately disadvantage LGBTQ+ people of color. Through this initiative, HRC will launch a public education campaign to change the narrative by focusing on dismantling stigma and discrimination while developing and advancing an inclusive public policy that addresses non-discrimination measures and healthcare disparities among LGBTQ+ communities.

"Too often, institutional racism and anti-LGBTQ+ bias have been barriers to comprehensive HIV prevention and treatment strategies," said Alphonso David, President of the Human Rights Campaign. "This grant will allow the Human Rights Campaign to work directly with community partners, Historically Black Colleges and Universities, and youth serving professionals – especially those in Black and Latinx communities in the South and around the country – to increase awareness of HIV treatment and prevention options in order to reduce health disparities, and combat the discrimination and stigma that too often leads to fatal violence against transgender women of color."

"Gilead is committed to promoting social justice and racial equity for the patients and communities we serve, as well as for our own employees," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "The grant to HRC builds on our commitment to advance equity in healthcare, particularly in Black communities and other communities of color that are disproportionately affected by HIV and other diseases."

Stigma, homophobia and transphobia, racism, and lack of access to appropriate healthcare services are barriers to comprehensive HIV prevention and care. This particularly impacts the 1 in 4 Latino gay and bisexual cisgender men and 1 in 2 Black gay and bisexual cisgender men who will be diagnosed with HIV in their lifetime. The funding from Gilead will enable HRC to work directly with these communities in the Southern U.S. and around the country, with partners including Us Helping Us in Washington, D.C. and Prince George's County, Maryland; Brotherhood Incorporated in New Orleans; TruEvolution in Riverside, California; Arianna's Center in Miami and San Juan, Puerto Rico; Community Health PIER in Greenville, Mississippi; and BU Wellness Network in Indianapolis. In addition, through this work, HRC will partner with more than 30 Historically Black Colleges and Universities to supplement their efforts in providing HIV prevention education and resources to students. The funding will also support HRC's Transgender Justice Initiative, which seeks to address the urgent needs of the transgender community, with specific attention to individuals deeply impacted by racism, sexism and transphobia.

HRC will host a virtual summit on February 23 featuring Alphonso David, HRC President and Shanell McGoy, Director, Public Affairs at Gilead, as well as advocates and community-based organization leaders, to discuss the efforts to end the HIV/AIDS epidemic in the U.S.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more than 30 years, Gilead has been a leading innovator in the field of HIV.

Gilead's social justice work includes a number of initiatives aimed at promoting equity, particularly healthcare equity, for individuals in underserved communities. The company has committed more than $100 million over 10 years through the Gilead COMPASS Initiative ® to community organizations in the Southern United States working to combat HIV/AIDS and in 2019 started the TRANScend ® Community Impact Fund to support organizations committed to improving the safety, health and wellness of the transgender community. In 2020, Gilead launched the Racial Equity Community Impact Fund, which is providing $10 million in funding to 20 organizations working to tackle racial inequities affecting Black communities across the United States.

About the Human Rights Campaign Foundation

The Human Rights Campaign Foundation is the educational arm of America's largest civil rights organization working to achieve equality for lesbian, gay, bisexual, transgender and queer people. Through 11 programs and initiatives, we seek to make transformational change in the everyday lives of LGBTQ people, with a clear focus on multiply marginalized people. We have transformed the landscape for more than 15 million workers, 10 million elementary school students, 600,000 clients in the adoption and foster care system, and so much more. We work each day to shed light on injustice and deepen the public's understanding. We provide direct consultation and technical assistance to institutions and communities, driving the advancement of inclusive policies and practices. We build the capacity of future leaders and allies through fellowship and training programs. And, with the firm belief that we are stronger working together, we forge partnerships with advocates in the U.S. and around the globe to increase our impact and shape the future of our work.

Gilead Contact:
Chris Ridley, Media
(650) 235-2220

HRC Contact:
Elizabeth Bibi, Media
(914) 874-6865

News Provided by Business Wire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×